Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arch Biopartners Inc (ACHFF)

Arch Biopartners Inc (ACHFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 75,989
  • Shares Outstanding, K 63,851
  • Annual Sales, $ 1,470 K
  • Annual Income, $ -2,470 K
  • 60-Month Beta 1.80
  • Price/Sales 51.87
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ACHFF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $-0.01 on 05/30/24
  • Next Earnings Date 09/03/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.01
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1600 unch
on 07/17/24
1.2600 -7.94%
on 06/21/24
-0.0500 (-4.13%)
since 06/17/24
3-Month
1.1500 +0.87%
on 06/17/24
1.7365 -33.20%
on 04/19/24
-0.5600 (-32.56%)
since 04/17/24
52-Week
0.7200 +61.11%
on 11/02/23
1.8800 -38.30%
on 03/18/24
-0.4201 (-26.59%)
since 07/17/23

Most Recent Stories

More News
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Shares for Interest Debt Settlement

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Unaware of Any Undisclosed Material Change

TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc....

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.600 (-0.62%)
ACHFF : 1.1600 (-2.53%)

Business Summary

Arch Biopartners Inc. is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation. Arch Biopartners Inc. is based in TORONTO.

See More

Key Turning Points

3rd Resistance Point 1.1850
2nd Resistance Point 1.1800
1st Resistance Point 1.1700
Last Price 1.1600
1st Support Level 1.1550
2nd Support Level 1.1500
3rd Support Level 1.1400

See More

52-Week High 1.8800
Fibonacci 61.8% 1.4369
Fibonacci 50% 1.3000
Fibonacci 38.2% 1.1631
Last Price 1.1600
52-Week Low 0.7200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar